WATSON PHARMACEUTICALS
Pharmaceutical company involved in generic pharmaceutical products.
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 3 of its records are shown together here.
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination 3rd Quarter 2013
|
RUBICON ADVISORS, LLC | — reported |
|
2nd Quarter - Report 2nd Quarter 2013
|
RUBICON ADVISORS, LLC | $98,000 reported |
|
1st Quarter - Termination 1st Quarter 2013
|
FIERCE, ISAKOWITZ & BLALOCK | $80,000 reported |
|
1st Quarter - Report 1st Quarter 2013
|
RUBICON ADVISORS, LLC | $98,000 reported |
|
4th Quarter - Report 4th Quarter 2012
|
RUBICON ADVISORS, LLC | $98,000 reported |
|
4th Quarter - Report 4th Quarter 2012
|
FIERCE, ISAKOWITZ & BLALOCK | $80,000 reported |
|
3rd Quarter - Report 3rd Quarter 2012
|
FIERCE, ISAKOWITZ & BLALOCK | $80,000 reported |
|
3rd Quarter - Report 3rd Quarter 2012
|
RUBICON ADVISORS, LLC | $98,000 reported |
|
2nd Quarter - Report 2nd Quarter 2012
|
FIERCE, ISAKOWITZ & BLALOCK | $80,000 reported |
|
2nd Quarter - Report 2nd Quarter 2012
|
RUBICON ADVISORS, LLC | $98,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| RUBICON ADVISORS, LLC | 25 | $2,542,000 |
| FIERCE, ISAKOWITZ & BLALOCK | 10 | $625,000 |
| STANTON PARK GROUP | 7 | $420,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Pharmacy | PHA | 26 |
| Copyright/Patent/Trademark | CPT | 17 |
| Medicare/Medicaid | MMM | 16 |
| Health Issues | HCR | 7 |
| Telecommunications | TEC | 6 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| H.R. 2100 | 112th | 8 |
| H.R. 1432 | 112th | 8 |
| H.R. 1908 | 112th | 8 |
| H.R. 5629 | 112th | 8 |
| H.R. 2100 | 111th | 8 |
| H.R. 1432 | 111th | 8 |
| H.R. 1908 | 111th | 8 |
| H.R. 5629 | 111th | 8 |
| S. 316 | 111th | 7 |
| S. 2029 | 111th | 7 |
| S. 27 | 112th | 6 |
| S. 1685 | 111th | 4 |
| H.R. 2100 | 110th | 4 |
| H.R. 5629 | 110th | 4 |
| S. 2029 | 110th | 4 |
| S. 316 | 110th | 4 |
| H.R. 1908 | 110th | 4 |
| H.R. 1432 | 110th | 4 |
| H.R. 5629 | 113th | 3 |
| H.R. 2100 | 113th | 3 |
| H.R. 1432 | 113th | 3 |
| H.R. 1908 | 113th | 3 |
| H.R. 1249 | 112th | 3 |
| S. 1882 | 112th | 2 |
| S. 214 | 113th | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.